Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging

玻璃体内注射康柏西普治疗伴有隐匿性脉络膜新生血管的慢性中心性浆液性脉络膜视网膜病变:一项基于多模态眼科影像的回顾性临床研究

阅读:1

Abstract

PURPOSE: This study aimed to evaluate the therapeutic efficacy and safety of intravitreal conbercept in patients with chronic central serous chorioretinopathy (cCSC) complicated by occult choroidal neovascularization (CNV), and to explore its potential in improving visual function and various ophthalmic parameters. METHODS: This retrospective, longitudinal, comparative study included 50 patients diagnosed with cCSC and occult CNV. Patients underwent intravitreal conbercept injections and were monitored over a six-month period. Comprehensive ophthalmic evaluation included best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) status, subfoveal choroidal thickness (SFCT), and optical coherence tomography angiography (OCTA). OCTA parameters such as foveal avascular zone (FAZ) area and CNV lesion characteristics were analyzed pre- and post-treatment. Patients were categorized based on changes in CNV lesion size to identify prognostic factors influencing treatment response. RESULTS: Significant improvements were observed in mean BCVA from baseline (0.78 ± 0.50 vs. 0.32 ± 0.31, p < 0.01) in all 50 eyes of the patients, except for one eye. Additionally, there were significant improvements in CMT, SRF status, SFCT, FAZ area, and CNV lesion size post-treatment (p < 0.05). Pearson correlation analysis indicated a positive correlation between baseline BCVA and CMT (r = 0.3615, p = 0.0116). Changes in BCVA post-treatment correlated with alterations in CMT, SRF diameter, and CNV lesion size. Patients with a favorable treatment response had significantly lower baseline CMT (312.17 ± 57.39 vs. 428.86 ± 114.54, p < 0.05) and CNV vessel diameter (17.46 ± 2.72 vs. 24.84 ± 4.02, p < 0.01) compared to those with unfavorable responses. CONCLUSION: Intravitreal conbercept injection was found to be safe and effective in improving BCVA and various ophthalmic parameters in patients with cCSC complicated by occult CNV, with no significant adverse effects observed during the study period. Baseline CMT, SRF diameter, CNV lesion size, and mean CNV vessel diameter were identified as valuable indicators for assessing treatment response and prognosis. These findings provide important insights for the clinical management and prognostic evaluation of cCSC patients with occult CNV, highlighting the utility of multimodal imaging in assessing treatment outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。